【レポートの概要（一部）】
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Glaucoma Overview 11
Therapeutics Development 12
Pipeline Products for Glaucoma – Overview 12
Pipeline Products for Glaucoma – Comparative Analysis 13
Glaucoma – Therapeutics under Development by Companies 14
Glaucoma – Therapeutics under Investigation by Universities/Institutes 18
Glaucoma – Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Glaucoma – Products under Development by Companies 23
Glaucoma – Products under Investigation by Universities/Institutes 29
Glaucoma – Companies Involved in Therapeutics Development 30
AC Immune SA 30
Acadia Pharmaceuticals Inc. 31
Aerie Pharmaceuticals, Inc. 32
Alcon, Inc. 33
Allergan, Inc. 34
Altacor Ltd. 35
Amakem NV 36
Asahi Kasei Pharma Corp. 37
AUS Bio Limited 38
Bausch & Lomb Incorporated 39
Bionure Farma, S.L. 40
Can-Fite BioPharma Ltd. 41
Cellular Biomedicine Group, Inc. 42
China Grand Wuhan General Pharmaceutical Research Institute 43
D. Western Therapeutics Institute, Inc. 44
DNAVEC Corporation 45
Dompe Farmaceutici S.p.A. 46
F. Hoffmann-La Roche Ltd. 47
Foamix Pharmaceuticals Ltd. 48
Gene Signal International SA 49
Gilead Sciences, Inc. 50
Handok Inc. 51
High Point Pharmaceuticals, LLC 52
Icon Bioscience, Inc. 53
IMMD Inc. 54
Inotek Pharmaceuticals Corporation 55
InSite Vision Incorporated 56
Lacer, S.A. 57
Merck & Co., Inc. 58
Merz Pharma GmbH & Co. KgaA 59
Mimetogen Pharmaceuticals Inc. 60
NeoStem, Inc. 61
Neurotech Pharmaceuticals, Inc. 62
NicOx S.A. 63
Ocata Therapeutics, Inc. 64
Ocular Therapeutix, Inc. 65
Ohr Pharmaceutical Inc. 66
Ono Pharmaceutical Co., Ltd. 67
Otsuka Holdings Co., Ltd. 68
Oxford BioMedica plc 69
PharmaNova Inc. 70
Quark Pharmaceuticals, Inc. 71
Santen Pharmaceutical Co., Ltd. 72
Senju Pharmaceutical Co., Ltd. 73
SIFI S.p.A 74
SK Biopharmaceuticals Co., Ltd. 75
Sun Pharma Advanced Research Company Ltd. 76
Sylentis S.A. 77
Teva Pharmaceutical Industries Limited 78
Upsher-Smith Laboratories, Inc. 79
Glaucoma – Therapeutics Assessment 80
Assessment by Monotherapy Products 80
Assessment by Combination Products 81
Assessment by Target 82
Assessment by Mechanism of Action 86
Assessment by Route of Administration 90
Assessment by Molecule Type 92
Drug Profiles 94
(AR-13324 + latanoprost) – Drug Profile 94
(bimatoprost + brimonidine tartrate) – Drug Profile 95
(carteolol hydrochloride + latanoprost) – Drug Profile 96
(dorzolamide hydrochloride + latanoprost) – Drug Profile 97
(latanoprost + trabodenoson) – Drug Profile 98
(Prostaglandin Agonist + Beta-Blocker) – Drug Profile 99
(tafluprost + timolol maleate) – Drug Profile 100
AC-262271 – Drug Profile 101
ACI-260 – Drug Profile 102
ACN-1052 – Drug Profile 103
aganirsen – Drug Profile 104
ALT-022 – Drug Profile 106
AMA-0076 – Drug Profile 107
Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy – Drug Profile 108
AP-022 – Drug Profile 109
APH-1104 – Drug Profile 110
AR-13324 – Drug Profile 111
AR-13533 – Drug Profile 112
ATS-8535 – Drug Profile 113
BA-1049 – Drug Profile 114
BA-240 – Drug Profile 115
bimatoprost – Drug Profile 116
bimatoprost SR – Drug Profile 117
BN-201 – Drug Profile 118
CF-101 – Drug Profile 119
CNS-102 – Drug Profile 122
DE-117 – Drug Profile 123
dorzolamide hydrochloride nanoparticle – Drug Profile 124
Drugs for Steroid Induced Glaucoma – Drug Profile 125
Drugs to Inhibit Cadherin-5 for Glaucoma – Drug Profile 126
Drugs to Target Bestrophin-2 for Glaucoma – Drug Profile 127
ENV-515 – Drug Profile 128
GB-201 – Drug Profile 129
GB-202 – Drug Profile 130
GB-203 – Drug Profile 131
GB-204 – Drug Profile 132
Gene Therapy for Glaucoma and Retinitis Pigmentosa – Drug Profile 133
Gene Therapy for Ocular Diseases – Drug Profile 134
Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension – Drug Profile 135
Glaucoma-GT – Drug Profile 136
GS-607601 – Drug Profile 137
H-1129 – Drug Profile 138
H-1129 Backup – Drug Profile 139
HL-5521 – Drug Profile 140
HPP-851 – Drug Profile 141
IMD-1041 – Drug Profile 142
KR-12 – Drug Profile 143
LA-8045 – Drug Profile 144
latanoprost – Drug Profile 145
latanoprost – Drug Profile 146
latanoprost – Drug Profile 148
latanoprost – Drug Profile 149
latanoprost SR – Drug Profile 150
latanoprostene bunod – Drug Profile 152
lomerizine – Drug Profile 154
Lycium Anti-Angiogenic Proteoglycan – Drug Profile 155
MD-920G – Drug Profile 156
MIMD-3 – Drug Profile 157
minocycline Gel – Drug Profile 158
Monoclonal Antibody to Activate Bves for Glaucoma – Drug Profile 159
MRZ-99030 – Drug Profile 160
NB-1111 – Drug Profile 161
NCX-1021 – Drug Profile 162
NCX-250 – Drug Profile 163
Neurovitas – Drug Profile 164
NT-501 – Drug Profile 165
NT-509 – Drug Profile 167
ONO-9054 – Drug Profile 168
OPA-6566 – Drug Profile 169
PBF-695 – Drug Profile 170
PRX-00933 – Drug Profile 171
QPI-1007 – Drug Profile 172
R-807 – Drug Profile 173
Recombinant Human Nerve Growth Factor – Drug Profile 174
RO-5093151 – Drug Profile 175
SF-103 – Drug Profile 177
SF-108 – Drug Profile 178
SF-109 – Drug Profile 179
SF-116 – Drug Profile 180
SKL-G – Drug Profile 181
SKS-1002 – Drug Profile 182
Small Molecule for Glaucoma – Drug Profile 183
Small Molecule for Glaucoma – Drug Profile 184
Small Molecule to Inhibit Rho Kinase for Glaucoma – Drug Profile 185
Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy – Drug Profile 186
Small Molecules for CNS Disorders and Ophthalmology – Drug Profile 187
Small Molecules to Activate sGC for Ophthalmology – Drug Profile 188
Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma – Drug Profile 189
Small Molecules to Antagonize TRPV4 for Glaucoma – Drug Profile 190
Small Molecules to Inhibit LIMK1 AND LIMK2 for Cancer and Ophthalmology – Drug Profile 191
SNJ-1656 – Drug Profile 192
SNJ-1945 – Drug Profile 194
Stem Cell Therapy for Glaucoma – Drug Profile 195
Stem Cell Therapy for Glaucoma, Cerebral Palsy and Lupus – Drug Profile 196
Stem Cell Therapy for Macular Degeneration and Glaucoma – Drug Profile 197
Stem Cell Therapy for Ophthalmic Disorders – Drug Profile 198
SYL-040012 – Drug Profile 199
Synthetic Peptide for Glaucoma – Drug Profile 201
tafluprost – Drug Profile 202
trabodenoson – Drug Profile 204
travoprost SR – Drug Profile 205
TRV-32R – Drug Profile 206
XY-0811QF2 – Drug Profile 207
XY-1303LT2 – Drug Profile 208
Glaucoma – Recent Pipeline Updates 209
Glaucoma – Dormant Projects 230
Glaucoma – Discontinued Products 232
Glaucoma – Product Development Milestones 233
Featured News & Press Releases 233
Appendix 242
Methodology 242
Coverage 242
Secondary Research 242
Primary Research 242
Expert Panel Validation 242
Contact Us 243
Disclaimer 243
【レポート販売概要】
■ タイトル：緑内障(Glaucoma)の治療薬パイプライン動向（2015年上半期版）■ 英文：Glaucoma - Pipeline Review, H1 2015
■ 発行日：2015年1月22日
■ 調査会社：Global Markets Direct
■ 商品コード：GMDHC6016IDB
■ 調査対象地域：グローバル
- 電気薬学/生体電気薬の世界市場：心臓ペースメーカー、人工内耳、脊髄刺激器、植込み型除細動器、脳深部刺激器The global electroceuticals/bioelectric medicine market is expected to reach USD 25.20 Billion by 2021 from USD 17.20 Billion in 2016, growing at a CAGR of 7.9% from 2016 to 2021. The global electroceuticals/bioelectric medicine market is segmented on the basis of product, type of device, application, end user, and region. By product, the market is categorized into implantable cardioverter defibri …
- 排出監視装置の世界市場：連続排出量監視システム（CEMS）、予測排出量監視システム（PEMS）The emission monitoring systems market is estimated to reach USD 2.81 Billion by 2020. Government regulations worldwide require industrial operators to measure the concentration of CO, NOx, O2, and other flue gases emitting from industrial process operations. Identifying the negative impact of these gases, many countries such as the U.S. and the U.K. have taken major steps to properly monitor and …
- モバイル政府の4Gクラウドサービス（4G Cloud Services for Mobile Governance）Cloud-enabled mobile governance has boundless opportunities for the public citizen, government agencies, and telecommunication companies. According to a survey released in December 2010 by the 1105 Government Information Group, cost reduction, fast access to data and applications, and simplifying IT infrastructure and management are the top three reasons that government agencies interest in incorp …
- 世界の大型トラック市場動向This latest just-auto report edition offers a global review of the heavy trucks sector, its manufacturers, top markets, technologies and market forecasts. This global market study offers: Heavy trucks market size estimates Latest technologies and trends Manufacturer production and sales volumes and forecasts Profiles of the major players including their strategies and prospects Market size forecas …
- 水平ドリルの世界市場2019-2023About this market The rising drilling activities in remote areas are impacting the horizontal directional drilling market growth during the forecast period. E&P companies are starting to explore unconventional avenues for exploration in remote areas. For instance, the Middle East, the Gulf of Mexico, and the North Sea have been witnessing a reduction in the rate of production. In addition, the ris …
- 世界の気管支鏡市場：製品気管支鏡別（フレキシブル、リジッド、EBUS）、イメージング装置別（モニター、カメラ）、アクセサリ別、作業チャネル直径別（2.8、2.2、3.0）、ユーザビリティ別（再利用可能、使い捨て）、エンドユーザー別（病院、ACS /クリニック）“The bronchoscopy market projected to grow at a CAGR of 5.9% during the forecast period (2019–2024).” The global bronchoscopy market is projected to reach USD 2.6 billion by 2024 from an estimated USD 2.0 billion in 2019, at a CAGR of 5.9% during the forecast period. The key factors driving the growth of this market include the growing demand for minimally invasive surgery, growing hospital invest …
- 世界の家電市場展望（～2015年）（Global Consumer Electronics Market Outlook 2015）The growing convergence of information, communication and entertainment is bringing a new era of consumer electronics across the world. Consumer electronics is one of the largest segments in the manufacturing industry and promises huge potential, particularly in emerging markets. With increasing household income levels, local manufacturing, launch of innovative technological products and rising aw …
- 創傷治療用生物製剤の世界市場：代用皮膚、成長因子About Wound Biologics Mechanical, chemical, thermal, and radiogenic damages can cause cuts, tears, and punctures in the skin, blood vessels, nerves, muscles, internal organs, bones, and joints. Wounds are of two types: acute and chronic. The reparative process in acute wounds occurs at a predictable and expected rate leading to faster healing, while it fails to occur in a predictable amount of tim …
- 医療レポート：Systemic Lupus Erythematosus-疫学予測（～2022）EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022 Summary Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of multifactorial origin that can affect any organ or organ systems, resulting in a broad spectrum of clinical manifestations ranging from dermatological involvement to multi-organ failure with episodes of relapses and remissions. The disease has unp …
- モバイルカードリーダーの世界市場2016-2020About Mobile Card Reader Mobile card readers are a major innovation in the payment industry, which has persuaded several enterprises that were reluctant to accept card payments to adopt them. The main difference between mobile card readers and traditional point-of-sale (PoS) solutions is the hardware used. Mobile card readers are smaller and can be attached to mobile devices such as smartphones or …
- 銅市場：ウクライナThis report is a comprehensive research of woodworking industry in Ukraine. The first two chapters of the report feature the country profile by giving general information on Ukraine and by thoroughly studying its economic state, (including key macroeconomic indicators and their development trends). The third chapter covers common business procedures in the country: from starting a project to closi …
- Leishmaniasis (Kala-Azar)：グローバル臨床試験レビューH1, 2013Leishmaniasis (Kala-Azar) Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Leishmaniasis (Kala-Azar) Global Clinical Trials Review, H1, 2013" provides data on the Leishmaniasis (Kala-Azar) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Leishmaniasis (Kala-Azar). It includes an overview of the trial …
- 世界のフリート管理市場：フリート解析、車両追跡、フリート・モニタリング、テレマティックス、ベンダー・サービスThe globally increasing demand for logistics and transportation has opened several business opportunities for the fleet management solutions. The report comprises of system components and technologies market growth for FMS. Rising fuel cost, requirement for operational efficiencies, increasing pollution issues, decreasing fleet management system components and connectivity costs are the key driver …
- 胆汁分泌停止(Cholestasis)：世界の治験レビュー（2015年上半期版）Cholestasis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Cholestasis Global Clinical Trials Review, H1, 2015" provides data on the Cholestasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cholestasis. It includes an overview of the trial numbers and their recruitment status as per the site of …
- Novoseven RT (Hemophilia A and B)：市場予測と分析（～2022）Novoseven RT (Hemophilia A and B) - Forecast and Market Analysis to 2022 Summary The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing th …
